Understanding genetic aberrations in lung cancer treatment: NTRK, RET, NRG

Updates on gastrointestinal cancer treatments ASCO 2025

Key updates on breast cancer treatments from ASCO 2025

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance

Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC

Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC

Independent clones in CLL show oligoclonality and early evolution patterns

Breast cancer survivorship

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results

Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective

Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia